Sorrento’s R&D is focused on driving innovation in cancer treatment, full pain control, autoimmune and COVID-19

Portfolio	Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Immuno-Oncology	CD38 CAR-T Multiple Myeloma 30%* CD38 DAR-T Multiple Myeloma 10%* CD38 ADC Amyloidosis 30%* Seprehvir™ Solid Tumors 30%*
Pain	RTX (resiniferatoxin) Epidural route Terminal Cancer Pain 55%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe OA 55%* RTX (resiniferatoxin) Intra-articular route TKR Deferment 10%* Pending designation
Lymphatic Delivery	Sofusa® anti-TNF Autoimmune 10%* Sofusa® anti-PD-1 CTCL 10%*
COVID-19 Programs	COVI-GUARD Antibody 10%* COVI-SHIELD Antibody Cocktail 10%* COVIDTRAP ACE2 Receptor Decoy 10%*

Immuno-Oncology
Key Programs (Indication)	Phase
CD38 CAR-T (Multiple Myeloma) Ph I CD38 DAR-T (Multiple Myeloma) Preclinical CD38 ADC (Amyloidosis) Ph I Seprehvir™ (Solid Tumors) Ph I

Pain
Key Programs (Indication)	Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II RTX (resiniferatoxin) Intra-articular route (TKR Deferment) Preclinical

Lymphatic Delivery
Key Programs (Indication)	Phase
Sofusa® anti-TNF (Autoimmune) Preclinical Sofusa® anti-PD-1 (Immuno Oncology) Preclinical

COVID-19 Programs
Key Programs (Indication)	Phase
COVI-GUARD Preclinical COVI-SHIELD Preclinical COVIDTRAP Preclinical